GlassScriptPhysician profile
Jacqueline Bomhoff
NPI 1932524048
$6,652.53
in general payments reported to CMS, 2019-2025
25 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $1,213 · 2023: $2,263 · 2024: $773 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,063.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,336.61 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Supernus Pharmaceuticals, INC. | $886.43 | 2021-2025 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $704.30 | 2022-2025 | |
| Corium, LLC | $478.85 | 2022-2025 | Azstarys |
| Neurelis, INC. | $436.52 | 2021-2025 | Valtoco |
| Sumitomo Pharma America, INC. | $228.11 | 2023 | Aptiom |
| Ironshore Pharmaceuticals INC. | $216.48 | 2022-2023 | Jornay Pm |
| Livanova USA, INC. | $176.45 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Sunovion Pharmaceuticals INC. | $166.52 | 2021-2022 | |
| Tris Pharma INC | $125.98 | 2023-2025 | Dyanavel Xr |
| Biohaven Pharmaceuticals, INC. | $124.50 | 2021 | |
| Sk Life Science, INC. | $84.78 | 2022-2023 | |
| Aucta Pharmaceuticals, INC. | $81.03 | 2025 | Motpoly Xr |
| Harmony Biosciences LLC | $73.42 | 2025 | |
| Immedica Pharma US, INC. | $72.64 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocodex, INC. | $66.65 | 2023 | Diacomit |
| Biogen, INC. | $65.05 | 2022-2023 | Spinraza |
| Aprecia Pharmaceuticals, LLC | $59.90 | 2022-2023 | Spritam |
| Greenwich Biosciences, INC. | $54.31 | 2021 | |
| Azurity Pharmaceuticals, INC. | $50.05 | 2022-2025 | Zonisade |
| Aquestive Therapeutics, INC. | $44.04 | 2022 | |
| Abbvie INC. | $35.79 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.11 | 2021-2022 | |
| Adlon Therapeutics L.P. | $34.99 | 2021 | |
| Eisai INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Bomhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.